bemarituzumab, irinotecan
Phase 2Small molecule
bemarituzumab, irinotecan is one of 37 small molecule programs targeting Adenocarcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
337 competitors in Adenocarcinoma
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 3
Taxotere
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Iressa
AstraZenecaPhase 3
Cyramza
Eli LillyPhase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
DATROWAY
Daiichi SankyoPhase 3
Erbitux
IImclone
Phase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Navelbine
PPierre Fabre Medicament
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Adenocarcinoma1 trial
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT06680622·126 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for bemarituzumab, irinotecan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details